Olivia Vizier

JPM: Aridis CEO Truong on why the pandemic hasn’t bolstered antibiotics R&D and what needs to change

With its pipeline of bacteria-fighting monoclonal antibodies, Aridis is working to tackle the first two problems: injecting innovation into the space and testing its programs in a way that show they’re better than the incumbents rather than simply not worse.

JPM: Aridis CEO Truong on why the pandemic hasn’t bolstered antibiotics R&D and what needs to change Read More »

Here’s What 4 Biopharma CFOs Think About The Future Of Remote Work

Office interactions are definitely an important way to foster relationships between coworkers, establish and maintain a corporate culture, and foster creative thinking. This is particularly relevant when a company onboards new employees. However, new technologies, such as the wide-spread use of high-quality video meeting platforms, have enabled us to replace the in-person interactions to some

Here’s What 4 Biopharma CFOs Think About The Future Of Remote Work Read More »

Health-Care Venture Capitalists Raised Record Total in 2020

Immuneering Corp., a Cambridge, Mass.-based startup that uses computational technology for drug discovery, completed a $62 million Series B round. Cormorant Asset Management led the financing, which included participation from Surveyor Capital, Rock Springs Capital, funds and accounts advised by T. Rowe Price Associates Inc., funds and accounts managed by BlackRock, Perceptive Advisors and LYFE

Health-Care Venture Capitalists Raised Record Total in 2020 Read More »

Using Computational Discovery to Build Better Immunotherapies

Compugen is using a computational discovery platform to identify proteins and pathways that drive immune resistance mechanisms to checkpoint inhibitors. We spoke to Anat Cohen-Dayag, CEO of Compugen, about the company’s discovery platform, its efforts to develop new treatments that address patients who don’t respond to current checkpoint inhibitors, and its clinical pipeline in development.

Using Computational Discovery to Build Better Immunotherapies Read More »

sleep review

What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk

The review received financial support from Avadel Pharmaceuticals, which recently filed a new drug application  with the US Food & Drug Administration (FDA) for a once-nightly formulation of sodium oxybate. Sodium oxybate is currently available with twice-nightly dosing from Jazz Pharmaceuticals under the brand name Xyrem. Jazz recently received FDA approval for narcolepsy drug Xywav

What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk Read More »

Immuneering secures $62M series B to advance tech-driven pipeline

Immuneering Corp., a bioinformatics specialist that has for years helped big companies like Teva Pharmaceutical Ltd. and Bristol Myers Squibb Co. better understand their own medicines, has landed $62 million in an oversubscribed series B financing that will help it leverage lessons learned in that journey to build out its own pipeline, starting with IMM-1-104,

Immuneering secures $62M series B to advance tech-driven pipeline Read More »

New and Emerging Drug Classes That Will Outlast the Pandemic

OncoSec’s vaccine, CORVax12, being developed in partnership with Providence Cancer Center in Portland, uses a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed in the National Institute of Allergy and Infectious Diseases (NIAID) laboratories similar to the one used in the newly approved Moderna vaccine. It is being created with a proprietary mixture consisting of Interleukin

New and Emerging Drug Classes That Will Outlast the Pandemic Read More »

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying For Rare Genetic Diseases | Podcast

Dr. Ragan discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma, and severe congenital neutropenia (SCN).

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying For Rare Genetic Diseases | Podcast Read More »

empowered

Developing Effective COVID-19 Oral Vaccine in Tablet Form with Sean Tucker Vaxart

Sean Tucker, Founder and Chief Scientific Officer, Vaxart is on a mission to expand the choices for a COVID-19 vaccine by producing an effective oral vaccine in tablet form which would allow for more efficient distribution and ease of administering particularly to needle-adverse people. Building on experience developing an oral tablet for an influenza vaccine,

Developing Effective COVID-19 Oral Vaccine in Tablet Form with Sean Tucker Vaxart Read More »

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression

We sit down with Dr. CJ Barnum, Director of Neuroscience at INmune Bio, Inc. to talk about the recently announced grant from the NIH for $2.9 million to test a new hypothesis that #neuroinflammation plays a major role in treatment resistant depression (TRD).

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression Read More »

6 CEOs Weigh In On The Supply Chain, Nationalism, And The Reshoring Of Biopharma Manufacturing

At a macro level across the globe, there is an increasing cadence, on an exponential curve, in the ability to translate basic insights into therapeutics. While the U.S. is still the world leader, other countries are making tremendous strides. The U.S. moving toward a more nationalistic framework has encouraged other countries, namely China, to own

6 CEOs Weigh In On The Supply Chain, Nationalism, And The Reshoring Of Biopharma Manufacturing Read More »

The Editors’ views: Drug Target Review’s 2020 round-up

GigaGen Inc.’s co-founder and Chief Executive Officer, explained that for decades scientists working with emerging pathogens had been concerned about the possibility of a pandemic, especially since funding decisions seemed more focused on the disease in question than the possible advantages a developing technology could provide. While many researchers may have redirected their work towards

The Editors’ views: Drug Target Review’s 2020 round-up Read More »

View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?

About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual Outlook issue. At least two of those questions, had they been asked just a month or so later, would have surely yielded very different responses than they did in December

View From The Inside: What’s Shaping Biopharma In 2021 And Beyond? Read More »